Highlights Newsletter 4 This newsletter presents you the following key sessions: Watch the video interview with Professor Jonathan Ledermann, MD, PhD, about the results of the phase III SOLO1 trial: maintenance with olaparib following chemotherapy results in a significant benefit in progression-free survival in patients with BRCA1/2 mutated advanced ovarian cancer Durable clinical benefit with nivolumab and low-dose ipilimumab in the first-line treatment of microsatellite instability (MSI)-high metastatic colorectal cancer Final overall survival data from PALOMA-3 assessing palbociclib plus fulvestrant in women with HR+/HER2- advanced breast cancer failing previous hormonal therapy Local radiotherapy improves survival in metastatic prostate cancer patients with low disease burden Chemoradiotherapy should remain the standard of care for patients with HPV-positive oropharynx cancer